Vimta Labs Limited (VIMTALABS.NS)
INR 1016.0
(2.42%)
INR 1016.0
(2.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 803.54 Million INR | -0.23% |
| 2022 | 805.39 Million INR | 10.0% |
| 2021 | 732.14 Million INR | -8.45% |
| 2020 | 799.75 Million INR | 9.83% |
| 2019 | 728.17 Million INR | 10.54% |
| 2018 | 658.75 Million INR | -17.86% |
| 2017 | 802.02 Million INR | -5.5% |
| 2016 | 848.68 Million INR | 71.47% |
| 2015 | 494.95 Million INR | 106.1% |
| 2014 | 240.15 Million INR | -16.15% |
| 2013 | 286.39 Million INR | -11.29% |
| 2012 | 322.84 Million INR | -30.98% |
| 2011 | 467.74 Million INR | -9.2% |
| 2010 | 515.12 Million INR | 0.77% |
| 2009 | 511.17 Million INR | 28.87% |
| 2008 | 396.64 Million INR | -10.63% |
| 2007 | 443.82 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -3.19 Billion INR | -497.86% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 803.54 Million INR | 0.0% |
| 2023 Q2 | 805.05 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 803.54 Million INR | -0.23% |
| 2022 FY | 805.39 Million INR | 10.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 836.71 Million INR | 0.0% |
| 2022 Q4 | 805.39 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 776.12 Million INR | 0.0% |
| 2021 FY | 732.14 Million INR | -8.45% |
| 2021 Q4 | 732.14 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 FY | 799.75 Million INR | 9.83% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 799.75 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 676.16 Million INR | 0.0% |
| 2019 Q2 | 690.85 Million INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 FY | 728.17 Million INR | 10.54% |
| 2019 Q4 | 728.17 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q2 | 776.28 Million INR | 0.0% |
| 2018 FY | 658.75 Million INR | -17.86% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 658.75 Million INR | 0.0% |
| 2017 Q2 | 827.94 Million INR | 0.0% |
| 2017 FY | 802.02 Million INR | -5.5% |
| 2017 Q4 | 802.02 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q4 | 848.68 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 848.68 Million INR | 71.47% |
| 2016 Q2 | 767.01 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 494.95 Million INR | 106.1% |
| 2015 Q4 | 494.95 Million INR | 0.0% |
| 2015 Q2 | 256.48 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q4 | 240.15 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 213.24 Million INR | 0.0% |
| 2014 FY | 240.15 Million INR | -16.15% |
| 2013 Q1 | - INR | -100.0% |
| 2013 FY | 286.39 Million INR | -11.29% |
| 2013 Q2 | 270.45 Million INR | 0.0% |
| 2013 Q4 | 286.39 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 Q4 | 322.84 Million INR | 0.0% |
| 2012 Q2 | 320.03 Million INR | 0.0% |
| 2012 FY | 322.84 Million INR | -30.98% |
| 2011 FY | 467.74 Million INR | -9.2% |
| 2011 Q4 | 467.74 Million INR | 0.0% |
| 2010 FY | 515.12 Million INR | 0.77% |
| 2009 FY | 511.17 Million INR | 28.87% |
| 2008 FY | 396.64 Million INR | -10.63% |
| 2007 FY | 443.82 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Krsnaa Diagnostics Limited | 3.62 Billion INR | 77.81% |
| Dr. Lal PathLabs Limited | 5.7 Billion INR | 85.918% |
| Metropolis Healthcare Limited | 4.55 Billion INR | 82.37% |
| Thyrocare Technologies Limited | 1.16 Billion INR | 30.878% |
| Vijaya Diagnostic Centre Limited | 3.22 Billion INR | 75.11% |